Sandbox/Alejandro: Difference between revisions

Jump to navigation Jump to search
Line 106: Line 106:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Oral Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Oral Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''[[Dicloxacillin]]''''' 250 mg PO q6h''''' <br> OR <br> ▸ '''''[[Cephalexin]]''''' 250 mg PO q6h''''' <br> OR <br> ▸ '''''[[Erythromycin]]''''' 250 mg PO q6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''[[Dicloxacillin]] 250 mg PO q6h''''' <br> OR <br> ▸ '''''[[Cephalexin]] 250 mg PO q6h''''' <br> OR <br> ▸ '''''[[Erythromycin]] 250 mg PO q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | <small> Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005<ref>{{Cite journal
| author = [[Dennis L. Stevens]], [[Alan L. Bisno]], [[Henry F. Chambers]], [[E. Dale Everett]], [[Patchen Dellinger]], [[Ellie J. C. Goldstein]], [[Sherwood L. Gorbach]], [[Jan V. Hirschmann]], [[Edward L. Kaplan]], [[Jose G. Montoya]] & [[James C. Wade]]
| title = Practice guidelines for the diagnosis and management of skin and soft-tissue infections
| journal = [[Clinical infectious diseases : an official publication of the Infectious Diseases Society of America]]
| volume = 41
| issue = 10
| pages = 1373–1406
| year = 2005
| month = November
| doi = 10.1086/497143
| pmid = 16231249
}}</ref></small>
|-
|-
|}
|}
Line 121: Line 134:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Oral Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Oral Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''[[Dicloxacillin]]''''' 12 mg/kg/day PO divided q6h''''' <br> OR <br> ▸ '''''[[Cephalexin]]''''' 25 mg /kg/day PO divided q6h''''' <br> OR <br> ▸ '''''[[Erythromycin]]''''' 40 mg/ kg/day divided PO q6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Dicloxacillin]] 12 mg/kg/day PO divided q6h''''' <br> OR <br> ▸ '''''[[Cephalexin]] 25 mg /kg/day PO divided q6h''''' <br> OR <br> ▸ '''''[[Erythromycin]] 40 mg/ kg/day divided PO q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | <small> Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005<ref>{{Cite journal
| author = [[Dennis L. Stevens]], [[Alan L. Bisno]], [[Henry F. Chambers]], [[E. Dale Everett]], [[Patchen Dellinger]], [[Ellie J. C. Goldstein]], [[Sherwood L. Gorbach]], [[Jan V. Hirschmann]], [[Edward L. Kaplan]], [[Jose G. Montoya]] & [[James C. Wade]]
| title = Practice guidelines for the diagnosis and management of skin and soft-tissue infections
| journal = [[Clinical infectious diseases : an official publication of the Infectious Diseases Society of America]]
| volume = 41
| issue = 10
| pages = 1373–1406
| year = 2005
| month = November
| doi = 10.1086/497143
| pmid = 16231249
}}</ref></small>
|-
|-
|}
|}
|}
|}
|}
|}

Revision as of 20:19, 29 May 2014

IMPETIGO

Medical Therapy

  • The treatment of impetigo depends on the location and number of lesions. Antibiotic therapy could be administered topically or orally.
  • Topical therapy is preferred for patients with small amount of lesions and without any bullae. [1]
  • Oral regimens are used for patients with several lesions and patients with bullous impetigo.
  • Non-medical therapy involves washing the lesions and the rest of the body with soap and water, and letting the impetigo dry in the air.
  • It is very important to remove the crusts before applying ointment, as the bacteria that cause the disease are located underneath them.
  • The recommended duration of therapy is 7 days but will depend on the clinical response.


▸ Click on the following categories to expand treatment regimens.

Bullous Impetigo

  ▸  Adults

  ▸  Children

Non-Bullous Impetigo

  ▸  Adults

  ▸  Children

Bullous Impetigo - Adults
Bullous Impetigo - Children
Preferred Regimen
PLUS
Alternative Regimen
Non-Bullous Impetigo - Adults
Topical Regimen
Mupirocin 2% apply to lesions q8h x 7 days
OR
Fusidic acid 2% apply to lesions q8h x 7 days
OR
Retapamulin 1% apply to lesions q12h x 5 days
Oral Regimen
▸ 'Dicloxacillin 250 mg PO q6h
OR
Cephalexin 250 mg PO q6h
OR
Erythromycin 250 mg PO q6h
Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005[2]
Non-Bullous Impetigo - Children
Topical Regimen
Mupirocin 2% apply to lesions q8h x 7 days
OR
Fusidic acid 2% apply to lesions q8h x 7 days
OR
Retapamulin 1% apply to lesions q12h x 5 days
Oral Regimen
Dicloxacillin 12 mg/kg/day PO divided q6h
OR
Cephalexin 25 mg /kg/day PO divided q6h
OR
Erythromycin 40 mg/ kg/day divided PO q6h
Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005[3]
  1. Sander Koning, Renske van der Sande, Arianne P. Verhagen, Lisette W. A. van Suijlekom-Smit, Andrew D. Morris, Christopher C. Butler, Marjolein Berger & Johannes C. van der Wouden (2012). "Interventions for impetigo". The Cochrane database of systematic reviews. 1: CD003261. doi:10.1002/14651858.CD003261.pub3. PMID 22258953.
  2. Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter |month= ignored (help)
  3. Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter |month= ignored (help)